No good deed goes unpunished. Successful development of a PD-1/PD-L1 checkpoint blocker, for example, can get you a grilling by Richard Pazdur, director of the FDA's Oncology Center of Excellence at the annual meeting of the American Association for Cancer Research (AACR).